Phoenix Financial Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY

Phoenix Financial Ltd. boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 110.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 106,154 shares of the biopharmaceutical company’s stock after acquiring an additional 55,624 shares during the period. Phoenix Financial Ltd.’s holdings in Bristol Myers Squibb were worth $4,789,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Brighton Jones LLC raised its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC increased its position in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares in the last quarter. Patton Fund Management Inc. acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $213,000. Patton Albertson Miller Group LLC boosted its stake in Bristol Myers Squibb by 17.3% during the 2nd quarter. Patton Albertson Miller Group LLC now owns 5,574 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 824 shares during the last quarter. Finally, V Square Quantitative Management LLC boosted its stake in Bristol Myers Squibb by 5.2% during the 2nd quarter. V Square Quantitative Management LLC now owns 48,828 shares of the biopharmaceutical company’s stock worth $2,260,000 after purchasing an additional 2,429 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.0%

Shares of Bristol Myers Squibb stock opened at $54.67 on Tuesday. The stock has a 50 day moving average of $52.72 and a 200 day moving average of $48.45. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The firm has a market capitalization of $111.29 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BMY. Scotiabank reissued a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Leerink Partners lifted their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.86.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.